Evidence map›Paper›PMID 23185003›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2012

Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions.

Caroline N Jones, Jesmond Dalli, Laurie Dimisko, Elisabeth Wong, Charles N Serhan, Daniel Irimia

Open access · greenAbstract readValidation Study
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Resolvin D2 restores monocyte anisocytosis and mediates a shift toward classical monocytes ex vivo in blood samples from patients after major burns.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Caroline N JonesCenter for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Shriners Hospital for Children, Boston, MA 02114, USA.
Jesmond Dalli
Laurie Dimisko
Elisabeth Wong
Charles N Serhan
Daniel Irimia
Harvard University · USMassachusetts General Hospital · USBrigham and Women's Hospital · USShriners Hospitals for Children - Erie · US

Funding

Bio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4M
BLOOD CELL LIPOXYGENASE PRODUCTS: FORMATION AND ACTIONR01GM038765 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 1992 to 2020
$4.9M
Neutrophil Decision Making in Confined Environments in Health and DiseaseR01GM092804 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI IRIMIA, DANIEL · 2010 to 2022
$4.3M
BLOOD CELL LIPOXYGENASE PRODUCTS--FORMATION AND ACTIONR37GM038765 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2000 to 2009
$4.0M
Novel Mechanisms in Resolution to Harness Inflammation for ReconstructionR01DE019938 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI IRIMIA, DANIEL, SERHAN, CHARLES NICHOLAS · 2009 to 2012
$2.7M
BLOOD CELL LIPOXYGENASE PRODUCTS--FORMATION &ACTIONR29GM038765 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 1987 to 1991
–
NIBIB NIH HHS P41 EB002503NIDCR NIH HHS DE19938NIDCR NIH HHS R01 DE019938NIGMS NIH HHS GM038765NIGMS NIH HHS R01 GM038765NIGMS NIH HHS R01 GM092804NIGMS NIH HHS R37 GM038765
6 · The paper itself

Abstract

Leukocyte trafficking plays a critical role in determining the progress and resolution of inflammation. Although significant progress has been made in understanding the role of leukocyte activation in inflammation, dissecting the interactions between different leukocyte subpopulations during trafficking is hampered by the complexity of in vivo conditions and the lack of detail of current in vitro assays. To measure the effects of the interactions between neutrophils and monocytes migrating in response to various chemoattractants, at single-cell resolution, we developed a microfluidic platform that replicates critical features of focal inflammation sites. We integrated an elastase assay into the focal chemotactic chambers (FCCs) of our device that enabled us to distinguish between phlogistic and nonphlogistic cell recruitment. We found that lipoxin A(4) and resolvin D1, in solution or incorporated into nano-proresolving medicines, reduced neutrophil and monocyte trafficking toward leukotriene B(4). Lipoxin A(4) also reduced the elastase release from homogenous and heterogenous mixtures of neutrophils and monocytes. Surprisingly, the effect of resolvin D1 on heterogenous mixtures was antisynergistic, resulting in a transient spike in elastase activity, which was quickly terminated, and the degraded elastin removed by the leukocytes inside the FCCs. Therefore, the microfluidic assay provides a robust platform for measuring the effect of leukocyte interactions during trafficking and for characterizing the effects of inflammation mediators.

Indexed as

Cell MovementChemotaxis, LeukocyteDocosahexaenoic AcidsEquipment DesignHumansInflammationLeukocytesLipoxinsMicrofluidic Analytical TechniquesMonocytesNanotechnologyNeutrophilsPancreatic ElastaseDocosahexaenoic Acidslipoxin A4LipoxinsPancreatic Elastaseresolvin D1

Identifiers

PMID23185003
PMCPMC3528552
OpenAlexW2158341765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.